- Previous Close
1.0600 - Open
1.0600 - Bid 0.9921 x 200
- Ask 1.0300 x 200
- Day's Range
0.9999 - 1.0800 - 52 Week Range
0.7710 - 3.1200 - Volume
189,672 - Avg. Volume
248,016 - Market Cap (intraday)
87.353M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.96
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
www.cardiolrx.com18
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CRDL
View More
Performance Overview: CRDL
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRDL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRDL
View MoreValuation Measures
Market Cap
87.35M
Enterprise Value
65.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.43%
Return on Equity (ttm)
-138.47%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-36.68M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
30.58M
Total Debt/Equity (mrq)
0.64%
Levered Free Cash Flow (ttm)
-11.86M